NGM Biopharmaceuticals raised $359 million across several funding rounds, including a $50M Series C (2013), a $57.5M Series D tranche (Feb 2015), and a major $106M Series D round (Mar 2015) led by Merck and top biotech investors. Founded in 2007, the company develops biologics targeting cardio-metabolic and liver diseases such as NASH and bile-acid disorders. Funding supported clinical trials, R&D, manufacturing scale-up and partnerships. These investments helped accelerate NGM’s pipeline toward advanced development stages and grow its capabilities in metabolic and liver therapeutics.